Amgen recalls certain lots of Aranesp

After observing cellulose and/or polyester particles in a small number of pre-filled syringes of Aranesp (darbepoetin alfa) during a routine quality check, Amgen (AMGN) initiates a voluntary recall of nine lots of the product.

Evaluations by the company found a very low potential to impact patients who may have received an affected product. However, the FDA determined that the health implications depend on a number of variables. Patients injected with a solution containing particulate foreign matter could experience chronic and acute inflammatory and/or allergic responses that could be life-threatening.

None of the recalled lots were distributed in the U.S. The lots were shipped to various countries in Europe and the Middle East.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs